Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sacituzumab Govitecan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Trodelvy

    02 2Trodelvy - U.S.

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Trodelvy - U.S.

    Sacituzumab Govitecan

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Trodelvy - U.S.

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Sacituzumab Govitecan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 49

    2019 Revenue in Millions : 0

    Growth (%) : Acquired by Gilead from Immunomedics

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Trodelvy - U.S.

    Sacituzumab Govitecan

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Trodelvy - U.S.

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Sacituzumab Govitecan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 380

    2020 Revenue in Millions : 49

    Growth (%) : 676

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Trodelvy

    Sacituzumab Govitecan

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Trodelvy

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Sacituzumab Govitecan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 680

    2021 Revenue in Millions : 380

    Growth (%) : 79

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Trodelvy

    Sacituzumab Govitecan

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Trodelvy

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Sacituzumab Govitecan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,063

    2022 Revenue in Millions : 680

    Growth (%) : 56

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF